Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug

被引：0
|
作者：
Ranganath, V. K. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
ARTHRITIS RESEARCH & THERAPY | 2005年 / 7卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Propensity Score; Rheumatoid Factor; Generalize Match;
D O I：
10.1186/ar1687
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [32] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [33] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [34] THE IMPACT OF EDUCATION ON ADHERENCE TO TREATMENT WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS
    Holc, I.
    Pahor, A.
    Gradisnik, S.
    Dai, K.
    Krajnc, M. Koren
    Grobelsek, V. Kovacic
    Dobnik, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 706 - 707
  • [35] Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis
    Mok, MY
    Ng, WL
    Yuen, MF
    Wong, RWS
    Lau, CS
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2000, 18 (03) : 363 - 368
  • [36] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [37] Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients
    Liu, Yi-Han
    Lin, Tzu-Chieh
    Yang, Yea-Huei Kao
    Chang, Hui-Jen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 73 - 73
  • [38] An audit of disease modifying anti-rheumatic drug (DMARD) therapy use in rheumatoid arthritis patients at a district general hospital
    King, Jonathan
    Mewinska, M.
    O'Rourke, Killian
    Laversuch, Catherine
    Cook, Lorraine
    Jewell, Theresa
    RHEUMATOLOGY, 2008, 47 : II138 - II138
  • [39] Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
    Nandakumar, Varun
    Baraff, Aaron
    Peterson, Alexander
    Smith, Nicholas
    Barton, Jennifer
    O'Hare, Ann
    Li, Christopher
    Weiss, Noel
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2851 - 2853
  • [40] Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment
    Smith, Malcolm D.
    Weedon, Helen
    Papangelis, Virginia
    Walker, Jennifer
    Roberts-Thomson, Peter J.
    Ahern, Michael J.
    RHEUMATOLOGY, 2010, 49 (05) : 862 - 875
12345